Integrative Insights Into DYRK1A From Molecular Function to Therapeutic Advancement

Area of Science:

• Biochemistry
• Medicinal Chemistry
• Pharmacology

Background:

• Dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) is a key target in Alzheimer's disease, Parkinson's disease, and cancer.
• DYRK1A's location in the Down syndrome critical region highlights its role in developmental disorders.
• Developing selective DYRK1A inhibitors is challenging due to its complex biological roles.

Purpose of the Study:

• To compile comprehensive structure-activity relationship (SAR) insights for medicinal chemists designing selective DYRK1A inhibitors.
• To provide a framework for understanding DYRK1A inhibitor classes and optimization strategies.
• To accelerate the rational design and clinical translation of DYRK1A therapeutics.

Main Methods:

• Detailed analysis of the DYRK1A ATP-binding pocket architecture and key regulatory residues.
• Review of structure-function relationships for ATP-competitive inhibitors, ATP-non-competitive inhibitors, and PROTAC degraders.
• Emphasis on functional group modifications and scaffold optimization strategies for inhibitor design.

Main Results:

• Actionable insights into binding mode predictions and potency-selectivity trade-offs.
• Guidance on prioritizing lead compounds for preclinical validation.
• Framework for optimizing pharmacokinetic properties and selectivity profiling across kinase families.

Conclusions:

• Medicinal chemists can leverage SAR insights to design more effective and selective DYRK1A inhibitors.
• Optimized inhibitor design strategies will facilitate the development of novel therapeutics for neurodegenerative and developmental disorders.
• This review aids in accelerating the translation of DYRK1A-targeted therapies into clinical trials.